Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Chordoma × Afatinib × Sarcoma × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Rhabdomyosarcoma 1 Neuroectodermal Tumors 1 Chordoma 1 Cancers Harbouring an EGFR Mutation, (Excluding Non-squamous Non- Small Cell Lung Cancer, a Registered Indication), a HER2 Mutation or a HER3 Mutation 1 Advanced Solid Tumors 1

Interventions

Nivolumab 6 Imatinib Mesylate 4 Ipilimumab 3 palbociclib 2 Specimen Handling 2 Radiosurgery 2 Protons 2 Proton Therapy 2 Pemetrexed 2 Magnetic Resonance Spectroscopy 2 Cyclophosphamide 2 Cetuximab 2 tazemetostat 1 spartalizumab 1 relatlimab 1 pembrolizumab 1 camrelizumab 1 avelumab 1 atezolizumab 1 apatinib 1 Zoledronic Acid 1 X-Rays 1 Tiragolumab 1 Thiotepa 1 Surveys and Questionnaires 1 Radiotherapy, Intensity-Modulated 1 Radiotherapy 1 Radiation 1 Photochemotherapy 1 Phantoms, Imaging 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03083678 2025-02-13

Afatinib in Locally Advanced and Metastatic Chordoma

Leiden University Medical Center

Phase 2 Completed

Chordoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡